Growing Adoption of Synthetic Peptide Drugs Driving Peptide Therapeutics Market at 5.94% CAGR by 2031

Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).
[https://www.skyquestt.com/report/peptide-therapeutics-market] size was valued at USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). The increasing prevalence of cancer and metabolic disorders such as osteoporosis, obesity and diabetes are expected to increase the use of peptide therapies in the coming years. The number of pediatric patients suffering from these diseases, widespread in low-income areas, need affordable supplies and effective drugs.

The market is expected to grow at a lucrative CAGR during the forecast period as companies focus on developing new drugs. Players have engaged in extensive research and development (R&D) activities to develop targeted therapies and increase their market share. Research and development in peptide therapeutics has focused on metabolism, followed by oncology and infectious diseases. Regulations for peptide therapies are seeing a shift toward more stringent requirements for efficacy, safety, and quality standards for approval. Regulatory agencies such as the FDA and EMA are actively developing new guidelines to refine the approval of peptide therapies.

Request your free sample PDF of the report today: https://www.skyquestt.com/sample-request/peptide-therapeutics-market

Business Verticals a Magnified Version of the Competitive Landscape in the Peptide Therapeutics Market

The competitive landscape in the peptide therapeutics market is characterized by interactions between established pharmaceutical giants, biotechnology companies and emerging players each with distinct competitive advantages.

Pharmaceutical Giants: The peptide therapeutics market is dominated by large pharmaceutical companies with huge investments in R&D and a global presence. Companies such as Eli Lilly, Novo Nordisk and Amgen are using their strong financial strength to develop broader peptide-based drugs, especially in areas such as diabetes and oncology.

Innovative research and development: Innovation in drug discovery and technology development is a key driver of competitiveness. Companies are investing heavily in new peptides that can be developed for specific diseases. For example, Eli Lilly's efforts to develop peptide-based drugs for diabetes, such as its breakthrough drug Trulicity, have helped secure a leading position.

For a tailored report, contact us to request a free customization: https://www.skyquestt.com/speak-with-analyst/peptide-therapeutics-market

Strategic Cooperation and Partnership

November 2022: Anterom developed one of the first immunotherapies based on its bacterial mimicry of drug recognition. Anterom reported safety, immunomodulatory, and efficacy data from its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor, for the treatment of patients with glioblastoma.

September 2022: Life science group Sartorius, through its French-listed subsidiary Sartorius StedimBiotech, acquired Albumedix Ltd. Albumedix is one of the leaders in recombinant albumin-based solutions.

This report covers following segments:

A. Application

Cancer

Metabolic

Cardiovascular Disorder

Respiratory

Gastrointestinal Diseases (GIT)

Anti-Infection

Pain

Dermatology

Central nervous system (CNS)

Renal

Others

B. Type of Manufacturers

In-house

Outsourced

C. Type

Generic

Innovative

D. Route of Administration

Parenteral

Oral

Pulmonary

Mucosal

Others

E. Synthesis Technology

Solid Phase Peptide Synthesis (SPPS)

Liquid Phase Peptide Synthesis (LPPS)

Hybrid Technology

This report covers the following players:

Amgen, Inc.

AstraZeneca plc

Bachem Holding AG

Bristol-Myers Squibb Company

Eli Lilly and Company

Ipsen S.A.

Merck & Co., Inc.

Novartis AG

Novo Nordisk A/S

Pfizer Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Lonza Group AG

Ferring Pharmaceuticals, Inc.

PolyPeptide Group

Protagonist Therapeutics, Inc.

Ipsen Biopharmaceuticals, Inc.

Polytherapeutics Inc.

Zealand Pharma A/S

Purchase now to gain valuable insights and stay informed: https://www.skyquestt.com/buy-now/peptide-therapeutics-market

Unlocking Future Potential in the Peptide Therapeutics Market

The peptide therapeutics market is poised for significant growth, driven by advances in drug delivery systems, increasing focus on precision medicine, expanding applications in oncology, metabolic disorders and infectious diseases. Peptides offer unique advantages such as high specificity and low toxicity, making them ideal for targeted therapies. With ongoing research, partnerships, and new technologies, the future of peptide therapies promises to deliver new treatments, improve patient outcomes, and be the next generation of medicine.

To read the full report, please visit: https://www.skyquestt.com/report/peptide-therapeutics-market

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=growing-adoption-of-synthetic-peptide-drugs-driving-peptide-therapeutics-market-at-594-cagr-by-2031]
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/peptide-therapeutics-market



This release was published on openPR.